Chronic Kidney Disease

Decreased serum albumin levels can be a tool for predicting the risk of cancer and mortality in patients undergoing hemodialysis.

Findings from a meta-analysis show peritoneal dialysis might preserve cognitive function compared to hemodialysis in chronic kidney disease.

In a cross-sectional OCTA analysis of patients with referable diabetic retinopathy, CKD emerges as an independent predictor of higher MA burden.

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

A competing mortality-risk model improves calibration and captures more true 5-year kidney failure events.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Bhatt discusses the positive results from the phase 2 trial of quarterly and monthly doses of investigational IL-6 inhibitor pacibekitug.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

Neuen is joined by Richard Pratley, MD, and Muthiah Vaduganathan, MD, MPH, to discuss the evolving landscape of CKM trial design.

A trio of experts and a patient advocate discuss unmet needs and recent innovations in kidney transplantation, from xenotransplantation to continuous hypothermic machine perfusion.